$0.83
3.00% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US43906K1007
Symbol
HOOK
Sector
Industry

Hookipa Pharma, Inc. Stock price

$0.83
-0.57 40.65% 1M
-3.23 79.63% 6M
-1.19 58.96% YTD
-6.65 88.96% 1Y
-20.18 96.07% 3Y
-82.18 99.01% 5Y
-139.18 99.41% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.03 3.00%
ISIN
US43906K1007
Symbol
HOOK
Sector
Industry

Key metrics

Market capitalization $9.95m
Enterprise Value $-28.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.38
EV/Sales (TTM) EV/Sales -0.66
P/S ratio (TTM) P/S ratio 0.23
P/B ratio (TTM) P/B ratio 0.19
Revenue growth (TTM) Revenue growth 118.32%
Revenue (TTM) Revenue $43.95m
EBIT (operating result TTM) EBIT $-44.79m
Free Cash Flow (TTM) Free Cash Flow $-77.17m
Cash position $39.78m
EPS (TTM) EPS $-3.55
P/S forward 1.47
EV/Sales forward negative
Short interest 0.91%
Show more

Is Hookipa Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Hookipa Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Hookipa Pharma, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Hookipa Pharma, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Hookipa Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
44 44
118% 118%
100%
- Direct Costs 2.75 2.75
23% 23%
6%
41 41
148% 148%
94%
- Selling and Administrative Expenses 15 15
28% 28%
33%
- Research and Development Expense 69 69
21% 21%
156%
-42 -42
48% 48%
-96%
- Depreciation and Amortization 2.75 2.75
23% 23%
6%
EBIT (Operating Income) EBIT -45 -45
47% 47%
-102%
Net Profit -44 -44
47% 47%
-99%

In millions USD.

Don't miss a Thing! We will send you all news about Hookipa Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hookipa Pharma, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Neutral
GlobeNewsWire
about one month ago
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Neutral
GlobeNewsWire
3 months ago
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
More Hookipa Pharma, Inc. News

Company Profile

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its product includes VaxWace and TheraT. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, Katherine Cohen, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

Head office United States
CEO Malte Peters
Employees 87
Founded 2011
Website www.hookipapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today